Zobrazeno 1 - 4
of 4
pro vyhledávání: '"MESH: Hydroxychloroquine / therapeutic use"'
Autor:
Lionel Piroth, Bruno Mourvillier, Joy Mootien, François-Xavier Lescure, Emmanuel Faure, S. Gallien, Dominique Costagliola, Jean-Christophe Richard, Noemie Mercier, Florent Wallet, Yazdan Yazdanpanah, Marion Noret, Claire Andrejak, Jean-Philippe Lanoix, Julien Poissy, Johan Courjon, Saad Nseir, François Danion, Violaine Tolsma, Alain Makinson, Odile Launay, Raphaël Clere-Jehl, Bruno Lina, Drifa Belhadi, Valérie Pourcher, Antoine Kimmoun, Karine Lacombe, Juliette Saillard, Maude Bouscambert-Duchamp, Stéphane Jauréguiberry, Charles Burdet, Toni Alfaiate, Olivier Epaulard, Minh Patrick Lê, Gilles Peytavin, Elisabeth Botelho-Nevers, Thérèse Staub, Guillaume Martin-Blondel, Alpha Diallo, Lila Bouadma, Aline Dechanet, François Goehringer, Florence Ader, Nathan Peiffer-Smadja, Jean-Christophe Navellou, Christelle Delmas, Rostane Gaci, Kevin Bouiller, Maya Hites, André Cabié, Jean Reuter, Sylvie Leroy, Axelle Dupont, François Raffi, Amandine Gagneux-Brunon, Jean Reignier, Clément Dubost
Publikováno v:
Clinical Microbiology and Infection
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, S1198-743X (21), pp.00259-7. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, S1198-743X (21), pp.00259-7. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
International audience; Objectives: We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in coronav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a8dd207add00814d32d637b7eef3ab
https://hal.archives-ouvertes.fr/hal-03364426
https://hal.archives-ouvertes.fr/hal-03364426
Autor:
Vincent Minville, Guillaume Martin-Blondel, Jacques Izopet, Stein Silva Sifontes, Rosine Guimbaud, Stéphanie Ruiz, Karen Delavigne, Didier Concordet, Pierre Delobel, Grégory Pugnet, Marlène Murris, Stanilas Faguer, Bernard Georges, Jean-Michel Mansuy, Véronigue Duhalde, Peggy Gandia, Jean-Marie Conil, Yves Rolland, Frédéric Eyvrard
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, ⟨10.1093/cid/ciaa558⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (11), pp.2962-2964. ⟨10.1093/cid/ciaa558⟩
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, ⟨10.1093/cid/ciaa558⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (11), pp.2962-2964. ⟨10.1093/cid/ciaa558⟩
Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d888ada4af45710e3a7a8801b9bc028
https://hal.archives-ouvertes.fr/hal-03010371
https://hal.archives-ouvertes.fr/hal-03010371
Autor:
Lamazou, F., Oger, P., Dieli-Crimi, Romina, Guerin, A., Letouzey, V., Octernaud, S., Place, V., Calès, P., Descamps, P., Delaroche, L., Universitat Autònoma de Barcelona
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-5 (2020)
BMC Infectious Diseases, BioMed Central, 2020, 20, pp.845. ⟨10.1186/s12879-020-05551-0⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-5 (2020)
BMC Infectious Diseases, BioMed Central, 2020, 20, pp.845. ⟨10.1186/s12879-020-05551-0⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Background In December 2019, a new disease (COVID-19) caused by a novel coronavirus called SARS-CoV-2 emerged in China and spread to many other countries. There is only limited data about the clinical features of COVID-19 during pregnancy, especially
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::155715d3817069f47fe66d607a7f93e2
https://ddd.uab.cat/record/253096
https://ddd.uab.cat/record/253096
Autor:
Salvatore Valitutti, Olivier Hermine, Carle Paul, Michel Lavit, Pol André Apoil, Michel Laroche, Camille Laurent, Cristina Bulai Livideanu, Eric Espinosa
Publikováno v:
Clinical Immunology
Clinical Immunology, Elsevier, 2018, 194, pp.75-79. ⟨10.1016/j.clim.2018.07.004⟩
Clinical Immunology, Elsevier, 2018, 194, pp.75-79. ⟨10.1016/j.clim.2018.07.004⟩
International audience; There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (n = 2) and mast cell activation syn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d403c91c3d746af7b3d007496109814
https://hal-univ-tlse3.archives-ouvertes.fr/hal-03284513
https://hal-univ-tlse3.archives-ouvertes.fr/hal-03284513